systematic review, targeted treatments, biologics, clinical trial, belimumab, anifrolumab, Bruton’s Tyrosine Kinase, BTK, inhibitor, evobrutinib, SLE, systemic lupus erythematosus, dose-ranging, pregnancy, obstetric comorbidities, , childhood-onset SLE (cSLE), treatment, safety, CD40 ligand, dapirolizumab pegol, exposure-response, population pharmacokinetics
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial
ACR Open Rheumatol. 2023;5(1):38–48 doi: 10.1002/acr2.11511
Results of a phase II trial of evobrutinib suggest that Bruton's Tyrosine Kinase (BTK) inhibition is not an efficacious therapeutic intervention over standard of care therapy for patients with SLE.
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901
Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.
Race, Ethnicity, and Disparities in Risk of End-organ Lupus Manifestations Following SLE Diagnosis in a Multiethnic Cohort
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24892
California Lupus Epidemiology Study (CLUES) finds heightened risks of developing renal, haematologic, and multiorgan disease following SLE diagnosis among Hispanic and Asian patients with SLE.